Andrea De Censi

Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial

Oriana Nanni, D. Amadori, Andrea De Censi et al. · Breast Cancer Research and Treatment · 2018 · 108 citations · Full text

Medicine, Oncology, Pharmacology +15

Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper

René Rizzoli, Jean‐Jacques Body, Andrea De Censi et al. · Osteoporosis International · 2012 · 105 citations · Full text

Medicine, Endocrinology, Oncology +17

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2021 · 89 citations · Full text

Medicine, Oncology, Pharmacology +17

Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies

Matteo Lambertini, Marcello Ceppi, Francesco Cognetti et al. · European Journal of Cancer · 2016 · 44 citations

Medicine, Oncology, Pharmacology +14

Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study

Gennaro Daniele, Francesco Raspagliesi, Giovanni Scambia et al. · International Journal of Gynecological Cancer · 2021 · 36 citations

Medicine, Gynecology, Oncology +17